Saffron (Crocus sativus) as an adjuvant therapy for chronic schizophrenia

Saffron (Crocus sativus) as an adjuvant therapy for the treatment of negative symptoms in patients with chronic schizophrenia : A randomized double blind and placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N140

Enrollment

Registered

2021-11-11

Start date

2021-12-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Patients treated with risperidone 4-6 mg (p.o) per day (Johnson & Johnson, Canada) + saffron capsule 15 mg (p.o.) twice per day (Institute of Medicinal Plants, ACEC

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of schizophrenia based on DSM-5 The score less than 14 based on HARS Age range: 18-60 years At least, 4 months treated with Risperidone

Exclusion criteria

Exclusion criteria: Diagnosis of another disorder in axis II Diagnosis of a significant neurological or systemic disease, acute or chronic History of central nervous system surgery Treatment with ECT during the last 3 months

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026